WATERTOWN, Mass.–(Business WIRE)–Lyndra Therapeutics, a scientific-phase biotechnology enterprise doing work to make every day supplements a thing of the past with the very first-at any time extremely-long-acting, sustained launch oral therapies, nowadays introduced the appointments of Abigail Jenkins as Chief Industrial and Small business Officer, and Jacqueline Fernandes as Vice President of Information Compliance and Facts Technological know-how.
“We are pleased to be growing Lyndra’s government crew with the appointment of two expert and attained industry executives. Each women of all ages fill important positions at Lyndra as we continue on to grow and situation ourselves for the acceptance of 5 solutions by 2025,” reported Dr. Patricia Hurter, Main Executive Officer of Lyndra Therapeutics. “Abigail’s track record for combining science, strategic organizing and eyesight to establish and guide successful professional health care operations will be priceless to the Business as Lyndra innovations from the scientific to industrial phase with the initiation of our very first pivotal demo of LYN-005 as a when-weekly oral remedy for schizophrenia afterwards this 12 months. Also, Jacqueline’s many years of expertise developing strategic IT frameworks to assure compliance, protection and scalability across growing businesses will permit fast and streamlined development throughout all facets of the business enterprise.”
Abigail Jenkins, Main Professional and Business enterprise Officer
Ms. Jenkins delivers to Lyndra more than 20 yrs of practical experience as a business and small business chief throughout growing general public existence sciences organizations with a successful report of setting up buyer-centric companies that develop benefit by delivering meaningful merchandise to marketplace. Most lately, Ms. Jenkins served as Senior Vice President and Business Unit Head of Vaccines at Emergent BioSolutions, Inc., the place she oversaw the Company’s biggest therapeutic division from discovery by way of commercialization. Prior to that, she held a sequence of govt and senior management roles at Aquinox Pharmaceuticals, Relypsa Inc. (now a Vifor Pharma Group Business) and Actavis Inc. (now aspect of AbbVie), as well as MedImmune Inc. (now aspect of AstraZeneca) and Pfizer. Ms. Jenkins holds a Master of Science degree in biotechnology and biotech business business from The Johns Hopkins University, and a Bachelor of Arts in psychology and biology from Indiana College.
“I’m pretty fired up to work alongside this passionate and pushed crew of healthcare pioneers doing the job to basically improve the way individuals all over the environment take drugs,” explained Ms. Jenkins. “I seem ahead to creating the basis for thriving commercialization of Lyndra’s strong pipeline as nicely as forging innovative field partnerships as the Company prepares for its next stage of company expansion.”
Jacqueline Fernandes, Vice President of Knowledge Compliance and Info Engineering
Ms. Fernandes delivers to Lyndra more than two many years of knowledge building and employing strategic and thorough info and IT compliance systems to help a extensive selection of intricate lawful, regulatory and compliance requirements at substantial general public, private and point out federal government corporations, like founded biotech and biopharma companies. Earlier, Ms. Fernandes served as Senior Director of Facts Compliance and Chief Privateness Officer at Sarepta Therapeutics Inc., wherever her perform led to major raises in cross-useful data acquisition, use, defense, stability and transparency to assist the Company’s world wide functions. In addition, she earlier served in senior-stage roles at Sunovion Pharmaceuticals Inc., The Condition of Massachusetts, Department of Transportation, Intel and Comcast. She also ran her have independent consulting firm for several several years. Ms. Fernandes holds a Learn of Science in information and facts security from Brandeis College and a Bachelor of Science in enterprise administration from Northeastern University.
“Lyndra is poised for substantial in close proximity to- and long-term growth and transformation as the Business proceeds to advance its novel extremely-prolonged-performing oral therapies,” claimed Ms. Fernandes. “I’m keen to lead to this significant work by making sure and enabling safe and sound and compliant processes that safeguard the organization and its stakeholders.”
About Lyndra Therapeutics
Lyndra Therapeutics is groundbreaking the first-ever oral, ultra-extensive-acting, sustained launch therapies, which have the probable to essentially change the way men and women consider medicine by enabling individuals to take a capsule as soon as a 7 days rather than day-to-day. The Company’s breakthrough Prolonged-Launch Oral Capsule is designed to supply dependable drug concentrations for an whole 7 days or as extended as a thirty day period, from one, regular-sized capsule – one thing no oral remedy has ever attained ahead of. Lyndra’s robust pipeline is made up of therapies with established and properly-regarded protection profiles throughout a number of condition areas in which non-adherence is known to be a important driver of results, which include schizophrenia and other central anxious process conditions, diabetic issues, cardiovascular illness and opioid abuse problem, between other people. The Firm is also dedicated to advancing its system across new chemical entities and a variety of critical international and public overall health alternatives along with partners these types of as the Invoice & Melinda Gates Basis and the NIH. For extra info, go to the Company’s web-site at www.lyndra.com.